In this episode, Meri shares his journey from VC to founder, the evolution of Lindus, and the transformative role of AI in clinical trials and drug development. Discover key patterns in team building, fundraising strategies, and the future of AI-powered healthcare innovations.
Meri is Co-CEO at Lindus, an Accountable Research Organisation (ARO) designed to give biotech and pharma sponsors confidence and control over their clinical trials.
In this episode, Sam and Meri also discuss:
Now We Build has partnered with Capquest, an equity and investor relations management platform built for founders who need to track SAFEs, manage their cap table, and keep investors updated without the spreadsheet chaos. If you're raising capital or managing equity, Capquest helps you stay organised from day one. Now We Build listeners can now get 20% off an entire annual subscription with the code nowwebuild20. Use the link here to claim the discount: https://capquest.io/book-demo
Timestamps:
00:00 Introductions & sponsors
01:45 Background
04:31 Transition from VC to Founder
07:16 The Birth of Lindus
10:06 Validating the Idea for Lindus
13:08 The Anti-CRO Model
15:46 Challenges in the Early Days
18:33 Scaling Operations and Hiring
21:33 Reflections on Growth Stages
24:48 Navigating Investor Relationships
26:27 The Evolution of Citrus and AI in Clinical Trials
29:50 AI's Impact on Clinical Trials
30:59 Building a Company with AI
35:03 Quickfire Insights and Reflections
Learn more: https://linktr.ee/nowwebuild
Did you enjoy this interview? Subscribe so you don’t miss out on future episodes.
Follow Meri:
LinkedIn: https://www.linkedin.com/in/meri-beckwith/
Follow Sam:
LinkedIn: https://www.linkedin.com/in/sam-marchant/
TikTok: https://www.tiktok.com/@sammrchant
Instagram: https://www.instagram.com/sammrchant
","author_name":"Sam Marchant"}